Announcing AI-Native Market Access Product for Regulated Products

Learn More

Blogs

MedTech

The role of regulatory affairs teams throughout the product lifecycle

By

Karen Cohn

March 9, 2023

4 min read

The lifecycle of a medical device

The time from when a medical device enters the market to the time it leaves, and the business and regulatory processes associated with that journey, are referred to as a product lifecycle. Regulatory affairs (RA) professionals have responsibilities at each stage of the product lifecycle and will collaborate with most sections of the business on one or more activities. In this article, we discuss the regulatory responsibilities that are typical in a large, global medical device manufacturer.

Cross collaboration with RA across the globe

The Regulatory Affairs professional at the manufacturer often does not complete regulatory activities alone. Major medical manufacturers have RA employees stationed across the globe. The international RA employees or local distributor will provide insight into their country’s regulatory requirements and will often be the individuals that have direct contact with their country’s government agency.  

For example: When a manufacturer is working on a Registration in China, the Regulatory Affairs Engineer in the U.S. may be on an 8pm call coordinating with a Regulatory Affairs Professional in China.  

Manufacturing RA Responsibilities

  • Provide details and information on the medical device.
  • Assist in-country RA in providing manufacturing SME team support on governmental questions during submission review.
  • Provide appropriate documentation from the SME teams to help complete the regulatory submission.

In-country RA Responsibilities

  • Provide insight on the in-country medical device requirements.
  • Identify Standards particular to the country.
  • Manage in-country specific submission deliverables.
  • Identify devices that need to be provided for in-country testing (if applicable).

Each major lifecycle stage – pre-market, market placement, and post-market – are discussed below.

Pre-market

Research and development

A new medical device begins with an idea for a product and an R&D process that will eventually include the quality and regulatory departments. Once designed, these devices are heavily tested to industry standards that are applicable to the device. Higher risk devices must also go through clinical trials before being brought to market. Information on compliance with standards and results from testing are included in the submission documents used to obtain market access.  

Each department plays a role in ensuring that a device and all supporting information is ready to request market entrance.

Regulatory responsibilities  

  • Identify applicable standards that will apply to the new device.
  • Collaborate with R&D to understand the functions of the new device.
  • Identify the intended use of the device.
  • Classify the device for major markets.
  • Collaborate with in-country RA for any additional device testing.

R&D responsibilities

  • Test the new device to the standards that regulatory tells them to or find a vendor that does that testing.
  • Compile the testing reports.

Business role responsibilities

  • Approve the financials for the R&D work.
  • Have an initial scope of regions where the device would be sold.

Initial business case

In parallel to the R&D preparation, a business plan will be developed by the Sales and Marketing teams, along with the Product and Project Managers (“business” teams). The business plan will detail where a product will be distributed and sold. It is incredibly important for the regulatory team to have a full understanding of this plan as early as possible so that they can research regulatory requirements and develop a regulatory plan.

The initial business case is often a back-and-forth conversation between those developing the business plan and the manufacturing and regulatory teams. The business often asks and heavily relies on the regulatory professional to describe the submission processes per country, to note any particularly challenging country for registration, and to explain why there are more requirements in some markets.

Regulatory Responsibilities

  • Notify the business of the cost of the submissions for all markets that the business intends to sell in (Market Access Submissions cost money).
  • Notify the business of the cost of man-hours on a per-registration basis.
  • Notify the business of the labeling costs.
  • Translating the manual into multiple languages.
  • Applying country-specific labeling on the package or on the device.

Business Responsibilities

  • Make good financial decisions on go-to-market.
  • Approve staffing resources for the regulatory activity.
  • Create a priority for submission activity.

Regulatory Plan

The regulatory department creates a plan of how to gain market access based on the initial business case. For large expansive launches in many countries, a regulatory plan may need to consider over 100 country requirements, which often includes a phased approach to product launches.

Regulatory responsibilities are often split between the RA resources at the manufacturer and those that are in the country in which the device is being marketed. While they vary by company, responsibilities often look something like this:

Manufacturing RA responsibilities

  • Draft the regulatory plan.
  • Provide classification for country of origin and some major markets.
  • Provide appropriate documentation from the SME teams to complete the regulatory submission.

In-country RA responsibilities

  • Provide insight on the in-country medical device requirements.
  • Classify the device per country standards.
  • Identify in-country specific submission deliverables that need manufacturing SME support.
  • Identify devices that need to be provided for in-country testing (if applicable).
  • Provide timeline estimations for international submissions.

Initial pre-market submissions

In regulated markets, a company needs to “register” their device prior to shipping, selling or marketing a device in the country. These submissions often contain confidential business information and test reports that were identified as needed in the regulatory plan. Once the device is accepted, a certificate is given to the manufacturer allowing the product to be sold in that market.

Typically, manufacturers begin by registering in their country of origin and a small subset of highly marketable countries. This phase often includes the USA and EU. Once a majority of those submissions are completed, submissions to other markets are addressed in a phased approach. There can be multiple waves of these registrations, and the entire registration process can last for months. Registration projects also often overlap for the manufacturing regulatory professional.  

Manufacturing regulatory responsibilities

  • Provide appropriate documentation from the SME teams to complete the regulatory submission.
  • Notify SME teams when support is needed.
  • Coordinate and compilate SME answers to governmental questions.
  • Update the business on the submission progress.
  • Notify the business when the submission is complete.

SME teams responsibilities

  • Provide adequate information about the device per the regulatory plan.
  • Notify the manufacturing regulatory team of any governmental questions and ask for support when needed.
  • Notify the manufacturing regulatory team of submission progress.
  • Provide SME support to develop the submission and answer governmental questions.

Business responsibilities

  • Provide funding for this activity.

Expansion to the rest of the globe

Once the initial launch is completed or near completion, submission activity now begins in every other market that the business approves to launch in. For large and expansive businesses, this launch can be over 100 countries, which can mean 100 regulatory product registrations.  

Manufacturing regulatory responsibilities

  • Provide appropriate device information to in-country RA for submission support.
  • Notify SME teams when support is needed.
  • Coordinate and compilate SME answers to governmental questions.
  • Update the business on the submission progress.
  • Notify the business when any submissions are complete.

In-country RA responsibilities

  • Complete in-country submission deliverables.
  • Identify standards particular to the country.
  • Manage in-country specific submission deliverables.
  • Identify devices that need to be provided for in-country testing (if applicable).

SME teams responsibilities

  • Provide adequate information about the device per the regulatory plan.
  • Provide SME support to develop the submission and answer governmental questions.

Rimsys provides regulatory teams with the ability to manage requirements, content plans, documents, and tasks for new registrations.

Marketing the device

Once a device is fully registered in the regulated country, it can be marketed. However, any marketing material that is created often goes through an additional legal and regulatory review as any inaccuracy can lead to fines for mislabeling the device.  

Manufacturing regulatory responsibilities

  • Coordinate with clinical to ensure claims are aligned.
  • Review marketing content to ensure regulatory compliance.
  • Notify the business when approvals are received so marketing knows when they can begin marketing the device in that country.

Marketing responsibilities

  • Create drafted content which could be product sheets, social media posts, or presentations for conferences.
  • Accept regulatory review of the marketing materials.

Market placement

Change management

Businesses add features and change medical devices all of the time. They may shift where the manufacturing facility is located, add an accessory, change a motor - all of these changes need to be assessed and submission may need to be done prior to market entry for those changes. These changes also need to be assessed on a global scale. The more countries that are involved, the more complex that process is.  

For every change, a survey is often sent out to the in-country regulatory teams, and they are often responsible for completing that assessment for their country. These are typically called impact surveys. It is then up to the RA team at the manufacturer to compile those responses and to receive approval from the business to complete any additional submissions to governments that may be required.

R&D responsibilities

  • R&D and project teams determine a change is needed.
  • Notify the manufacturing regulatory team of the upcoming change.

Manufacturing regulatory responsibilities

  • Fully understand the change that is coming from R&D.

In-country regulatory responsibilities

  • In-country specialist completes the impact survey.
  • Notify the manufacturing regulatory team if additional submission activity is needed, along with the timeline for that activity and the deliverables/support required.

Business responsibilities

  • Approve the submission activity and finance it as needed.

Renewals

After the initial submission, most countries will require a renewal submission after a set number of years to keep the device in the market. It is critical that renewal dates are tracked and managed appropriately. Missed renewal dates may require several months to over a year of work to obtain market approval again. During that time, all sales of the product are stopped.  

Manufacturing regulatory responsibilities

  • Notify the business of upcoming renewals.
  • Coordinate with in-country RA to provide documents and assist in the submission for the renewal.
  • Coordinate SME support for governmental questions if needed.

In-country regulatory responsibilities

  • Notify manufacturing regulatory in a timely manner when renewals are needed.
  • Submit the renewal to the government authority.

Business responsibilities  

  • Approve the renewals.

Rimsys simplifies global submission management with integrated tools that provide complete control over submission authoring, assembly, and publishing.

Post-market

Audits

Governments and other regulatory bodies will often audit the medical device manufacturer to ensure that they are in compliance with current regulations.  

Manufacturing regulatory responsibilities

  • Gathering device marketing registration history and facility registration for a specific set of countries to be presented by the auditor.
  • Familiarizing yourself with the registrations and recent regulatory work that has occurred in the country to be prepared for auditor's questions.  
  • Responding to auditors questions if you are on “Audit Duty”.

Quality department responsibilities  

  • Manage the facility tour.
  • Be responsible for the majority of the Quality Management System (QMS).

Research and development  

  • Provide the subject matter expert (SME) with explanations of how testing was developed for the product and the outcomes of said testing.

Post-market surveillance and reporting

Manufacturers must have ways of accepting customer complaints. In certain cases, when the complaints relate to health and safety concerns pertaining to the device, the manufacturer may need to report these complaints to their government or other countries where the device is sold.  

Correctional activities (recalls)

If a company finds a health and safety risk to their device, the company as a whole may need to gather all of the devices that are affected and either repair them or destroy them.

Obsolescence

Obsoleting a product is often a regulatory step and a submission step as well. There are many reasons to take a device out of a market; low sales, new requirements causing additional work that is not financially feasible, or new devices being available that are part of a newer generation that are safer for the user are a few reasons.  

Business responsibilities

  • Notify manufacturing RA and in-country marketing of the obsolescence of the device in the market.

Manufacturing RA responsibilities  

  • Notify in-Country RA of the obsolescence and expected date that the business will stop supporting the device in that market.

In-country RA responsibilities  

  • Submit obsolescence notification to the authority.

Learn more about how Rimsys supports the regulatory teams of some of the world’s leading Medtech companies.

‍

Similar posts

AI

From Regulatory Knowledge to Better Market Decisions: A Conversation with Steve Gens and James Gianoutsos

October 1, 2026

4 min read

AI is moving quickly from experimentation to implementation across life sciences. For regulatory teams, that raises a bigger question than where AI can automate a task:

How can organizations use AI to make better decisions while maintaining the traceability, expert oversight, and confidence regulatory work demands?

That was a central theme when James Gianoutsos, Founder and CEO of Rimsys, joined Steve Gens, Founder and Managing Partner of Gens & Associates, on the Regulatory Executive Podcast.

Their conversation explored the changing role of regulatory intelligence, the introduction of Rimsys Market Access, the importance of transparency in regulatory AI, and what these changes could mean for regulatory teams.

Regulatory knowledge has been difficult and costly to scale

For global medtech organizations, regulatory knowledge has traditionally been highly dependent on people.

A company may have specialists responsible for particular countries or regions, along with local representatives, distributors, consultants, and other experts. Those people develop deep knowledge of local regulations, pathways, and expectations.

The problem is that the knowledge often remains distributed across the organization. And maintaining that market-by-market expertise can become expensive as a company expands its portfolio and geographic footprint.

As James described during the podcast, large manufacturers may rely on dozens or even hundreds of internal employees, third-party distributors, local representatives, and other specialists to understand what it takes to bring products into different markets. Smaller organizations may rely more heavily on outside consultants and partners. Either way, the model can be costly and difficult to scale. 

But the cost isn't limited to what companies spend on expertise.

Steve described the workflow as a series of “start, stop” cycles: ask a local expert, verify whether the regulation is current, gather more information, and repeat. Each cycle consumes regulatory capacity and extends the time it takes to give the business a confident answer.

That creates another potentially more consequential expense: the cost of waiting.

When it takes months to understand what entering a market will require, commercial and product teams have less visibility into when revenue might begin, what resources will be needed, or whether the opportunity is worth pursuing. Regulatory teams spend valuable capacity assembling and validating information rather than applying their expertise to more strategic work.

Ultimately, scaling regulatory knowledge isn't simply an efficiency problem. It affects how quickly and confidently the business can decide where to invest.

The bigger question: Should we enter this market?

That challenge is central to Rimsys Market Access.

Most market-entry research begins with questions such as: How is the product classified? What's the regulatory pathway? What are the requirements?

Those questions establish whether a company can enter a market. But they don't necessarily tell the business whether it should.

Market Access is designed to help regulatory and commercial teams develop an earlier view of what market entry could involve, including classification, regulatory pathway, timeline, cost considerations, requirements and potential gaps. 

For commercial and product leaders, that provides greater predictability before committing budget and resources.

For regulatory leaders, it means starting with a structured plan rather than assembling every market assessment from scratch.

Moving regulatory knowledge from individuals into a shared system

During the conversation, James described one of AI's most significant opportunities as moving knowledge that has historically lived in people's heads into software.

The goal isn't to eliminate regulatory expertise. It's to make that expertise more scalable.

Market Access works from a curated regulatory corpus, allowing market-specific knowledge to be applied across workflows without requiring every initial question to go through the individual who happens to know that jurisdiction. Outputs are designed to trace back to the underlying regulation, guidance, or law. 

That can also change where regulatory professionals spend their time. Rather than focusing as heavily on finding information and assembling initial assessments, they can focus on reviewing the evidence, identifying gaps, applying judgment, and advising the business.

Steve described the concept as a subject-matter-expert assistant. James called it a workforce multiplier. 

Trust requires opening the regulatory AI “black box”

Speed isn't enough when the information is being used to inform regulatory decisions.

James and Steve returned repeatedly to the importance of knowing where an AI-generated answer comes from. As Steve summarized it during the discussion, transparency builds trust.

Market Access is designed around that principle. Its outputs are grounded in a curated regulatory corpus and traceable to the specific regulations, guidance, or laws supporting them. That gives regulatory professionals the ability to verify an answer rather than simply accept it. 

Human judgment remains essential as well. Market Access provides an upfront assessment, not a guarantee of a regulatory outcome. Reviewer interpretation and other factors can still affect what happens during the regulatory process.

The objective isn't to make uncertainty disappear. It's to make what is known, what the sources say, and where uncertainty remains much easier to see.

Connecting the market decision to execution

The discussion also pointed to a broader evolution in regulatory technology: moving from systems that primarily store regulatory information toward systems that help teams act on it.

That's where Market Access and Rimsys RIM play distinct but complementary roles.

Market Access is the planning layer. It helps teams determine whether, when, and how to enter a market.

Rimsys RIM is the execution layer. It manages the registrations, submissions, regulatory changes, and ongoing regulatory work required to act on that plan. 

Together, they create a path from the initial market decision through regulatory execution rather than leaving planning and execution disconnected.

A new role for AI in regulatory work

One of the most interesting themes from Steve and James's conversation was that AI's impact may ultimately be less about replacing individual tasks and more about expanding what regulatory teams can accomplish.

Better access to market-specific knowledge can help professionals work across more markets, spend less time gathering information, and devote more capacity to the judgment and strategic work that requires their expertise.

The technology is changing quickly, but the fundamentals of regulatory work remain: reliable information, domain expertise, transparency, and human judgment.

The opportunity is to apply those fundamentals at greater scale while giving the business a clearer answer to the question that comes before execution:

Not simply, “Can we enter this market?”

But, “Should we?”

Listen to the full conversation

Hear the complete discussion between Steve Gens, Founder and Managing Partner of Gens & Associates, and James Gianoutsos, Founder and CEO of Rimsys, on the Regulatory Executive Podcast for more on regulatory AI, market-entry planning, transparency, and the changing role of regulatory teams.

‍

AI

How Market Access Builds Trust in Regulatory Intelligence

By

Bethaney Lentz

September 18, 2026

4 min read

Why source traceability, regulatory specificity, and human judgment matter when AI informs a market-entry decision.

Regulatory professionals are not short on AI options. General-purpose tools can answer questions quickly and often sound convincing. But in medtech, a convincing answer is not the same thing as a decision you can defend.

That distinction matters most before a company commits to a new market. Teams need to understand how a product is classified, which pathway applies, how long entry may take, what it may cost, where the important gaps are, and what uncertainty still remains. Commercial leaders need that visibility to decide whether the opportunity is worth pursuing. Regulatory leaders need to know that the assessment is grounded in sources they can verify.

That is the trust standard behind Rimsys Market Access. It is not simply about producing regulatory information faster. It is about helping medtech teams decide whether, when, and how to enter a market before committing budget and resources, with outputs linked back to the regulations, guidance, and laws behind them.

Why fluency is not enough for regulatory work

A general AI tool can be useful for brainstorming, summarizing, and exploring a topic. The challenge comes when an answer has real regulatory consequences. A plausible response may still be incomplete, based on the wrong designation, or disconnected from the current source that should govern the decision.

Medtech makes this especially difficult because the same product can be treated differently across markets and product designations. Medical device, IVD, cosmetic, consumer, OTC, and combination-product considerations can change the regulatory read. A market-entry assessment has to account for that context rather than assume one answer travels cleanly from one jurisdiction to another.

For regulatory teams, the natural next question is: Where did this answer come from? If the system cannot show the underlying authority, the expert still has to rebuild the research before trusting the result. That limits the value of the speed AI was supposed to create in the first place.

Trust starts with a decision you can verify

Market Access is designed around a different outcome. The goal is not to give teams another stream of regulatory information to interpret. It is to provide a source-linked market plan that helps them answer the bigger business question: should we enter this market, not just can we?

For a market assessment, that can include classification, regulatory pathway, timeline, cost considerations, key requirements and potential gaps. The output is designed to give commercial and product leaders an earlier, more defensible view of the opportunity while giving regulatory professionals the detail they need to review the basis for the assessment.

Trust comes from being able to inspect that basis. Market Access works from a curated regulatory corpus spanning more than 200 markets rather than relying on the open web. Answers are linked to the specific regulation, guidance, or law behind them, so a regulatory professional can verify the source instead of being asked to accept an AI-generated conclusion on faith.

Three things make regulatory intelligence more defensible

1. Source traceability

A regulatory answer is more useful when the person reviewing it can follow the evidence. Market Access links outputs back to their underlying regulatory sources. That changes the review process from “Do I trust the AI?” to a more practical question: “Does the cited source support this conclusion for our product and situation?”

That is an important shift for regulatory teams. Instead of assembling every market assessment from a blank page, they can review a structured, sourced plan, challenge assumptions, and focus their expertise on the places where judgment matters most.

2. Regulatory specificity

Trust also depends on context. Market Access is purpose-built for medtech regulatory complexity and supports cross-designation classification. The objective is to evaluate the product in the context of the market and the applicable regulatory framework, then carry that context into the pathway, requirements, timeline, cost considerations, and gaps that shape the market-entry decision.

This is where a purpose-built market-planning platform differs from a generic chat experience. The value is not an impressive answer in isolation. It is a connected assessment that helps the team understand what entering the market is likely to require and whether the opportunity still makes sense once those requirements are visible.

3. Human judgment stays in control

No system can remove every area of uncertainty from regulatory work. Reviewer interpretation and expert judgment still affect outcomes, and Market Access is not designed to promise approval.

Instead, Market Access is designed to make uncertainty more manageable. Regulatory professionals review and validate the work before it moves into execution. They can verify sources, assess the gaps, and apply company and product context that software cannot fully replace. The technology accelerates the research and planning. The regulatory professional remains responsible for the judgment.

What trust looks like in a market-entry decision

Imagine a team evaluating several markets for a new product. The commercial question is not simply whether registration is technically possible. The team needs to know which markets deserve investment now, which may require more evidence or resources, and which could put the revenue window at risk because the pathway is longer or more complex than expected.

Regulatory has a different, but connected, need. They have to understand the classification and pathway, identify the requirements most likely to slow the submission, and confirm that the plan reflects the relevant regulatory sources.

Market Access brings those views together. Commercial and product leaders get earlier visibility into timing, cost considerations, requirements, and risk so they can build a stronger business case. Regulatory teams get a source-linked plan they can review rather than a collection of unsupported conclusions. Both groups are working from the same market-entry picture before significant resources are committed.

Trust is not the end goal. Better decisions are.

It is easy for a conversation about regulatory AI to become a conversation about models, agents, or architecture. Those details matter, but they are not the business outcome.

The real value of trustworthy regulatory intelligence is what it lets a team do next. It can help a commercial leader defend a market investment. It can help regulatory surface issues earlier. It can give both groups a more predictable view of the work ahead before budget, R&D capacity, or launch timing is locked in.

And once the decision is made, the work does not have to stop at an intelligence report. Market Access is the market-planning layer. Rimsys RIM is the execution layer for registrations, submissions, regulatory changes, and ongoing regulatory work. Each can stand on its own, and together they create a path from the market-entry decision into controlled execution.

A more useful standard for regulatory AI

The question for medtech teams should not be whether AI can produce a regulatory answer. It can. The better question is whether that answer is specific enough, traceable enough, and reviewable enough to support a real decision.

Market Access is built around that standard: a defensible view of whether, when, and how to enter a market, grounded in curated regulatory sources and kept under human review. Because when the decision affects revenue, resources, and regulatory strategy, sounding right is not enough. Teams need to see why the answer is right, where uncertainty remains, and what it means for the decision in front of them.

Company

Product Updates

Rimsys Announces AI-Native Market Access for Regulated Products

By

Bethaney Lentz

September 1, 2026

4 min read

New software gives regulatory and commercial leaders a source-linked, actionable view of market viability, requirements, timing, and risk before committing resources

PITTSBURGH, PA, September 1, 2026 - Rimsys, the heart of medtech regulatory operations, today announced Market Access, a new AI-native product designed to help companies determine whether a market is worth entering and what it will take to get there. Market Access will be available in beta beginning September 1, 2026, with general availability to be announced separately.

Market Access replaces what can be a 6-to-9-month research and assessment process with a same-day, actionable read on market viability. It gives regulatory and commercial leaders the classification, pathway, timeline, cost considerations, and potential regulatory gaps they need to make a more defensible investment decision before committing budget and resources.

Predictability is at the core of Market Access. Rather than simply identifying a regulatory pathway, it helps teams understand what to expect, which requirements or gaps are most likely to slow down a submission, and where uncertainty remains. Every answer traces back to the specific regulation, guidance, or law behind it, allowing regulatory professionals to verify the underlying source rather than simply trust an AI-generated response.

Key features and benefits include:

  • Same-day market assessment: Provides an actionable read on whether a market is worth entering, replacing research and assessment that can take 6 to 9 months.
  • Cross-designation classification: Evaluates products across medical device, IVD, cosmetic, consumer, and OTC designations, so the same product receives the appropriate regulatory read regardless of how a given market classifies it.
  • Clear market-entry requirements: Provides classification, regulatory pathway, timeline, cost considerations, and key requirements before teams commit resources.
  • Earlier visibility into regulatory gaps: Surfaces the specific requirements and gaps most likely to slow down a submission and helps teams understand their potential severity.
  • Greater predictability: Provides visibility into anticipated regulatory response windows, risks, and areas of uncertainty so teams can better plan for what lies ahead.
  • Source-linked intelligence: Traces answers to the underlying regulations, guidance, and laws so regulatory professionals can verify the basis for an assessment.
  • AI with human oversight: Uses Rimsys AI and Market Manager Agents to accelerate complex regulatory research while keeping regulatory professionals in control of review and validation.
  • Connected planning and execution: Complements RIM, connecting market-entry decisions with the registrations, submissions, regulatory changes, and ongoing compliance required to execute them.

“Regulatory knowledge has traditionally been highly dependent on individual expertise and market-by-market research,” said James Gianoutsos, Founder and CEO of Rimsys. “Market Access gives companies greater predictability before they make a market investment. Teams can understand whether an opportunity is worth pursuing, what it will take to enter, where regulatory challenges are likely to emerge, and what uncertainty remains. And because every answer is tied to its regulatory source, experts can verify the recommendation rather than simply trust the AI.”

Market Access is powered by Rimsys AI, which works from a curated regulatory corpus spanning more than 200 markets, not the open web. Its Market Manager Agents are AI agents with market-specific regulatory knowledge, including pathways, requirements, and documentation, that support market assessments and global launch planning. The product is also designed to acknowledge areas where reviewer interpretation and expert judgment can affect regulatory outcomes rather than presenting those outcomes as more predictable than they are.

Market Access expands the Rimsys product portfolio from regulatory execution into market planning. Market Access helps regulatory and commercial leaders determine where to compete, while RIM manages the registrations, submissions, regulatory changes, product data, and ongoing compliance required to enter and remain in those markets. Together, they turn regulatory intelligence into coordinated action, helping regulatory teams accomplish more in every hour while giving business leaders greater visibility into opportunities, risk, and the work required to protect and grow revenue.

Beta Availability

Market Access will be available in beta beginning September 1, 2026. During the beta period, Rimsys will continue validating product capabilities and refining workflows ahead of broader commercial availability. 

Organizations interested in learning more about Market Access or participating in the beta program can visit rimsys.io/products/market-access.

About Rimsys

Rimsys is the heart of regulatory operations, connecting AI-native market planning with AI-embedded regulatory execution, giving medtech manufacturers one living system from market-entry decision to execution. 

Rimsys Market Access is the planning layer, answering not just whether a market can be entered, but whether it should be, returning classification, pathway, timeline, and cost before a team commits budget or resources to finding out. Rimsys RIM is the execution layer, managing registrations, submissions, regulatory changes, and compliance so teams can act on that plan with confidence.

Trusted by 6 of the top 12 global MedTech manufacturers and certified to ISO 27001 and SOC 2, with ISO 42001 certification for AI management systems underway, Rimsys keeps regulatory intelligence, product data, approvals, and change management continuously connected so teams can enter new markets with speed and assurance. Learn more at rimsys.io.

Media Contact
letschat@rimsys.io

I agree to the privacy policy including to Rimsys using my contact details to contact me for marketing purposes.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Hand holding smartphone showing email app with 12 unread messages notification.